KRAS Inhibitor Reduces Progression Risk in Pretreated Lung Cancer

(MedPage Today) — Treatment with adagrasib (Krazati) significantly improved progression-free-survival (PFS) in previously treated patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC) compared with docetaxel, the phase III KRYSTAL…

Source link : https://www.medpagetoday.com/hematologyoncology/lungcancer/116919

Author :

Publish date : 2025-08-08 20:14:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
		1	2	3	4	5
6	7	8	9	10	11	12
13	14	15	16	17	18	19
20	21	22	23	24	25	26
27	28	29	30	31

KRAS Inhibitor Reduces Progression Risk in Pretreated Lung Cancer

Rapist Who Killed Visiting Nurse Gets 50 Years in Prison

A planet the size of Saturn could orbit the nearest Sun-like star

Related Posts

A Novel Way to Spot Gait Problems in Parkinson’s

‘Addictive’ UPF Intake More Prevalent in Older US Adults

Rising CVD Risks: Pregnancy an Opportunity to Screen

JAK Inhibitor Stays Effective Beyond 1 Year for Giant Cell Arteritis

‘If That Doesn’t Blow Your Mind’: What We Heard This Week

Tirzepatide-Hormone Therapy Combo Tied to Weight Loss in Postmenopausal Women

A Novel Way to Spot Gait Problems in Parkinson’s

‘Addictive’ UPF Intake More Prevalent in Older US Adults

Rising CVD Risks: Pregnancy an Opportunity to Screen

JAK Inhibitor Stays Effective Beyond 1 Year for Giant Cell Arteritis

‘If That Doesn’t Blow Your Mind’: What We Heard This Week

Tirzepatide-Hormone Therapy Combo Tied to Weight Loss in Postmenopausal Women

Prevention Has a Branding Problem

Pool Data Back Safety of Newly Approved Non-Hormonal Treatment for Hot Flashes

Categories

Archives